We're sorry but this page doesn't work properly without JavaScript enabled. Please enable it to continue.
Feedback

Mathematical predictions for brain tumor response to novel therapies validated by in vivo and in vitro experiments

Formale Metadaten

Titel
Mathematical predictions for brain tumor response to novel therapies validated by in vivo and in vitro experiments
Serientitel
Anzahl der Teile
11
Autor
Lizenz
CC-Namensnennung - keine kommerzielle Nutzung - keine Bearbeitung 4.0 International:
Sie dürfen das Werk bzw. den Inhalt in unveränderter Form zu jedem legalen und nicht-kommerziellen Zweck nutzen, vervielfältigen, verbreiten und öffentlich zugänglich machen, sofern Sie den Namen des Autors/Rechteinhabers in der von ihm festgelegten Weise nennen.
Identifikatoren
Herausgeber
Erscheinungsjahr
Sprache

Inhaltliche Metadaten

Fachgebiet
Genre
Abstract
Glioblastoma (GBM) is the most frequent and lethal malignant brain tumor in adults due to its invasive capability and resistance to conventional therapies. GBM typically shows an heterogenous microenviron- ment including necrotic and hypoxic areas, abnormal vasculature and different tumor cell phenotypes. We will focus on mathematical models based on PDE that try to reproduce this complex system in order to understand it and better predict the tumor behaviour [1, 2]. In addition, we will discuss in-silico simu- lations based on a mathematical model for brain tumor response to the combination of antithrombotic, antioxidants and radiation therapies [3]. Our mathematical results predict a synergistic decrease in tumor volume when both, cytotoxic therapies and antioxidants were applied. In vitro and in vivo results have confirmed this benefit not only in terms of tumor reduction but also in terms of toxicity reduction. Combined mathematical simulations and on-chip validation of malignant cellular structures formation in GBM have confirmed their usability to better understand the tumor behaviour [4, 5]. Considering the promising results, a clinical trial is being designed.